Potomac Urology is currently recruiting for the clinical trials listed on this page. Please contact us if you are interested in participating and want to learn more about enrollment.
Enlarged Prostate/Benign Prostatic Hyperplasia
Investigating Medication versus Prostatic Urethral Lift: Assessment and Comparison of Therapies for Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia, or BPH, is a condition in which the prostate enlarges as men get older. BPH is very common – in fact, over 40% of men in their 50’s and over 70% of men in their 60’s have BPH.1 As the prostate enlarges, it presses on and blocks the urethra, causing bothersome urinary symptoms such as:
- Frequent need to urinate both day and night
- Weak or slow urinary stream, and/or a stream that stops and starts
- A sense that you cannot completely empty your bladder
- Urgent feeling of needing to urinate
While prostate surgery is an option for some, these procedures often require general anesthesia and can also cause long-term side effects such as sexual dysfunction and urinary incontinence.
If you’re living with BPH and are interested in exploring non-surgical treatment options, you may qualify for the IMPACT Clinical Study. The study involves the UroLift® System treatment, an FDA-cleared device designed to relieve BPH symptoms through a simple outpatient procedure.
Development and Validation of Biomarker-based tests for Disease Progression in Prostate Cancer Patients
Phase 1 = Assess urine and blood samples in men with NCCN very low/low/favorable intermediate risk prostate cancer undergoing radical prostatectomy to rule in/out the presence of high-risk prostate cancer
Phase 2 = Assess urine and blood samples in men managed with active surveillance for prostate cancer to rule in/out the presence of high-risk prostate cancer
Randomized Study to Evaluate MACE in Patients with Prostate Cancer Treated with Relugolix or Leuprolide Acetate
A Multi-Center, Prospective, Observational Study of Patients Being Treated with Orgovyx (OPTYX)
This is a multi-center, prospective, observational study of patients being treated with ORGOVYX. The goal of this study is to generate real-world evidence about the safety and effectiveness of ORGOVYX in patients with prostate cancer in routine clinical care and the clinical course during treatment with and following cessation of ORGOVYX.
A Prospective Observational Multicenter Real-World Registry Assessing the Impact of the use of PYLARIFY® (piflufolastat F 18) PET in Patients with Newly Diagnosed and Recurrent Prostate Cancer
A Randomized Controlled Trial of Prostatak as Adjuvant to Up-front Radiation Therapy for Localized Prostate Cancer
**NOT CURRENTLY ENROLLING**
Dendreon Booster Study
Belzupacap sarotalocan (bel-sar, AU-011)
A Phase 1, open-label trial of belzupacap sarotalocan (AU-011) to determine the feasibility and safety of intratumoral injection with or without intramural injection in subjects with bladder cancer
Interested in a Clinical Trial?
If you’re interested in participating in one of the clinical trials listed above, call Nicholas Maksimowicz at (703) 680-2111 ext. 405 or Laura Mendoza at ext. 402 and reference the clinical trial ID number.
A Pivotal Cross-Sectional Study for Bladder Cancer Detection Using a Non-invasive Urinary Biomarker Uro17 in Patients with Suspected Bladder Cancer (KDx)
Prospective Collection of Urine Samples from Men Undergoing Prostate Biopsy (Select MDx)
Follow-up Evaluation of Men Previously Enrolled and Diagnosed with Prostate Cancer Who Underwent Radical Prostatectomy (Select MDx sub-study)
Immunophenotyping of Myeloid and Lymphoid Cells to Predict Prostate Cancer in At-Risk Men (Anixa)
A Randomized, Multicenter, Two-Arm, Single-Dose, Double-Blind, Placebo-CONtrolled Phase 3
Study of Intravesical QapzolaTM (Apaziquone) as a Chemotherapy Adjuvant to TransUrEthral Resection of Bladder Tumors in Patients with Low- to Intermediate- Risk Non-Muscle Invasive Bladder Cancer (CONQUER)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm Study to Assess the Safety and Efficacy of a Single Treatment of BOTOX, Followed by an Optional Open-Label Treatment with BOTOX, in Female Subjects with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)